• B. Riley upgrades NASDAQ:RDNT to a "Buy" rating and increases the price target from $71 to $87.
• DeepHealth, a subsidiary of RadNet, introduces next-generation AI-powered imaging solutions at RSNA 2025.
• Despite a slight decrease in stock price to $81.67, RadNet shows strong investor interest and market capitalization of approximately $6.3 billion.

RadNet, Inc. (NASDAQ:RDNT) is a prominent player in the healthcare sector, specializing in diagnostic imaging services. The company operates a network of outpatient imaging centers, providing a range of services including MRI, CT, and PET scans. RadNet's subsidiary, DeepHealth, focuses on AI-powered health informatics, enhancing the company's offerings with advanced technology solutions.

On December 1, 2025, B. Riley upgraded RDNT's stock to a "Buy" rating, with the stock priced at $82.79 at the time. B. Riley also increased the price target for RadNet from $71 to $87. This upgrade reflects confidence in RadNet's growth potential, likely influenced by DeepHealth's recent advancements in AI-powered imaging solutions.

DeepHealth, a wholly owned subsidiary of RadNet, has unveiled an expanded portfolio at RSNA 2025. The company introduced next-generation imaging informatics and clinical AI solutions, enhancing its offerings in disease detection, assessment, and monitoring. These innovations aim to transform the imaging experience and advance population health, aligning with RadNet's strategic goals.

Despite the positive developments, RDNT's stock is currently priced at $81.67, showing a decrease of 1.35% from the previous day. The stock has fluctuated between $81.01 and $82.28 today, with a market capitalization of approximately $6.3 billion. The trading volume for RDNT is 101,147 shares on the NASDAQ exchange, indicating active investor interest.

Kees Wesdorp, President and CEO of RadNet's Digital Health Division, emphasized the transformative potential of AI-powered imaging. DeepHealth aims to improve healthcare delivery by integrating AI across its portfolio, unifying clinical and operational intelligence. This strategic focus on AI could drive future growth and support the upgraded stock rating by B. Riley.